News Overview

Asian equities ended mixed as China and Hong Kong rebounded on lower oil prices, Japan edged higher, South Korea slipped slightly, and India fell below the 24K mark amid profit-taking and global uncertainty.

Dr. Reddy's Laboratories surged to a new 52-week high as optimism over its biologics pipeline, manageable USFDA observations, new product launches, and strong sector-wide momentum boosted investor confidence. Positive brokerage commentary and expectations of long-term earnings growth further strengthened the stock's rally.

The Indian stock market ended in the red on June 29, 2026, as renewed US-Iran tensions, higher crude oil prices, and profit booking weighed on investor sentiment. Nifty slipped to 23,946 while Sensex lost 372 points. Pharma stocks emerged as the top performers on biosimilar and export optimism, whereas Auto, IT, and Cement sectors witnessed broad-based selling amid cautious global cues.

Turtlemint Fintech Solutions made a muted stock market debut, listing at a discount on both NSE and BSE. Despite solid institutional interest, weak retail sentiment, negative GMP, and continued losses weighed on performance.

Suzlon Energy secures a 400 MW wind EPC order from Tata Power Renewables, boosting its order book and reinforcing its shift toward integrated EPC and DevCo-led renewable energy projects in India.

Bajaj Healthcare share price surged 15% after the company became the first in India to secure the SEC recommendation for Cenobamate tablets. The regulatory milestone is expected to strengthen its CNS portfolio and boost long-term growth prospects.

The Nifty Pharma Index outperformed the broader market by reaching a new 52-week high as pharmaceutical stocks rallied on expanding GLP-1 manufacturing, robust export demand, and positive long-term industry outlook.

Dr. Reddy's Laboratories shares climbed nearly 5% despite the USFDA issuing seven observations at its Bachupally biologics facility. Here's why investors viewed the development positively and what analysts expect next.

HDFC Bank shares rose after an independent legal review found no evidence supporting allegations made by former chairman Atanu Chakraborty. Jefferies and JPMorgan maintained bullish ratings, citing attractive valuations and improving governance clarity.

Aditya Vision reached a new 52-week high of ₹705 following robust FY26 financial performance, strong profit growth, and continued expansion across eastern India. The consumer electronics retailer benefited from rising demand in Tier-2 and Tier-3 markets, positive brokerage outlooks, institutional buying, and a bullish technical breakout, reinforcing its position as a leading regional retail growth story.